Merck KGaA (OTCMKTS:MKGAF – Get Free Report)’s stock price dropped 7.6% during mid-day trading on Friday . The company traded as low as $153.89 and last traded at $153.89. Approximately 8 shares traded hands during trading, a decline of 99% from the average daily volume of 598 shares. The stock had previously closed at $166.6010.
Merck KGaA Stock Performance
The company has a market cap of $21.02 billion, a price-to-earnings ratio of 24.83 and a beta of 0.96. The firm has a fifty day simple moving average of $163.93 and a 200 day simple moving average of $149.40. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.31 and a quick ratio of 0.84.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of the business. Elefante Mark B bought a new stake in shares of Merck KGaA during the second quarter worth $617,000. Ames National Corp bought a new position in Merck KGaA in the second quarter valued at approximately $1,009,000. Notis McConarty Edward bought a new stake in shares of Merck KGaA during the 2nd quarter valued at $1,304,000. North Star Asset Management Inc. acquired a new position in shares of Merck KGaA in the 2nd quarter valued at $1,411,000. Finally, Pinnacle Holdings LLC bought a new position in shares of Merck KGaA in the 2nd quarter worth $1,487,000. 0.10% of the stock is owned by institutional investors and hedge funds.
Merck KGaA Company Profile
Merck KGaA, headquartered in Darmstadt, Germany, is a long-established multinational chemical and pharmaceutical company with roots dating back to 1668. Operating under the brand Merck Group (and using distinct consumer-facing names in certain regions to avoid confusion with other companies of similar name), the company is privately controlled by the Merck family and organizes its activities across multiple business units that serve customers in Europe, the Americas, Asia-Pacific and beyond.
The company’s operations are organized mainly into three businesses.
Further Reading
- Five stocks we like better than Merck KGaA
- Revolution Medicines Got Its Breakthrough—What Moves It Next?
- Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
- FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism
- AST SpaceMobile Stock Soared 12%—This Was the Catalyst
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
